help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on June 15, 2006, doi:10.1165/rcmb.2005-0476OC

Am. J. Respir. Cell Mol. Biol., Volume 35, Number 5, November 2006, 587-592

A more recent version of this article appeared on November 1, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-0476OCv1
35/5/587    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhong, H.
Right arrow Articles by Zeng, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhong, H.
Right arrow Articles by Zeng, D.

Submitted on December 21, 2005
Revised on June 12, 2006

A2B Adenosine Receptors Induce IL-19 from Bronchial Epithelial Cells and Results in TNF-{alpha} Increase

Hongyan Zhong1*, Yuzhi Wu1, Luiz Belardinelli1, and Dewan Zeng1

1 Department of Drug Research and Pharmacological Sciences, CV Therapeutics, Inc., Palo Alto, CA, USA

* To whom correspondence should be addressed. E-mail: hongyan.zhong{at}cvt.com.

Adenosine is a signaling nucleoside that has been proposed to contribute to the pathogenesis of asthma and chronic obstructive pulmonary disease. Previous studies suggest that adenosine might play an important role in modulating levels of inflammatory mediators in the lung. Because airway epithelium is an important cellular source of inflammatory mediators, the objective of the present study was to determine whether adenosine affects the expression and release of inflammatory cytokines from human bronchial epithelial cells (HBECs). Among the four subtypes of adenosine receptors, the A2B receptor was expressed at the highest level. NECA, a stable analog of adenosine, increased the release of IL-19 by 4.6 ± 1.1 fold. A selective antagonist of the A2B receptor, CVT-6694, attenuated this effect of NECA. The amount of IL-19 released from HBEC was sufficient to activate a human monocytic cell line (THP-1) and increase the release of TNF-{alpha}. Furthermore, TNF-{alpha} was found to upregulate A2B receptor expression in HBECs by 3.1 ± 0.3 fold. Hence, these data indicate that NECA increases the release of IL-19 from HBECs via activation of A2B receptors, and IL-19 in turn activates human monocytes to release TNF-{alpha}, which upregulates A2B receptor expression in HBECs. The results of this study suggest that there is a novel pathway whereby adenosine can initiate and amplify an inflammatory response which might be important in pathogenesis of inflammatory lung diseases.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2006 American Thoracic Society.
  ATS Best of the Web